Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - C4 Therapeutics, Inc. | cccc-ex991_7.htm |
| 8-K - 8-K - C4 Therapeutics, Inc. | cccc-8k_20210112.htm |
Exhibit 99.2
Cash Guidance
Unaudited cash, cash equivalents and short-term investments as of December 31, 2020, were approximately $370 million. C4 Therapeutics, Inc. expects its cash, cash equivalents and short-term investments, including payments anticipated to be received under existing collaboration agreements, will be sufficient to fund its operating plan to the end of 2023.
ACTIVE/106555018.1